Medicine and Dentistry
Multidrug Resistant Tuberculosis
100%
Bedaquiline
87%
Drug Resistant Tuberculosis
84%
Delamanid
78%
Adverse Event
67%
Tuberculosis Treatment
57%
Systematic Review
50%
Public Health
48%
Meta-Analysis
47%
Infection
47%
Health Care Cost
43%
Extensively Drug Resistant Tuberculosis
39%
COVID-19
39%
Silo-Filler's Disease
35%
Rifampicin
25%
Lung Tuberculosis
23%
Clinical Management
23%
Therapeutic Drug Monitoring
23%
Nicotine Withdrawal
23%
Personalized Medicine
23%
Rehabilitation Engineering
23%
Mixed Infection
23%
Intensive Care Unit
23%
Intensive Care
23%
Medicine
23%
Epidemic
23%
Virus Infection
23%
Patient-Data
23%
Human Immunodeficiency Virus
23%
Drug Sensitivity
21%
Linezolid
21%
Pulmonary Rehabilitation
17%
Mycobacterium Tuberculosis
17%
Tuberculostatic Agent
17%
Moxifloxacin
17%
Likert Scale
16%
Culture Conversion
16%
Disease
15%
Middle East Respiratory Syndrome
15%
Influenza A (H1N1)
15%
Severe Acute Respiratory Syndrome
15%
Prophylaxis
15%
Pandemic
15%
Patient Care
14%
Clinician
14%
Counseling
14%
Cardiovascular Disease
13%
Levofloxacin
13%
Sputum Smear
11%
Carbapenem
11%
Keyphrases
Bedaquiline
87%
Multidrug-resistant Tuberculosis (MDR-TB)
82%
Delamanid
70%
Tuberculosis
56%
Linezolid
52%
Systematic Meta-analysis
47%
Europe
47%
Extensively Drug-resistant Tuberculosis
35%
Moxifloxacin
29%
Rifampicin-resistant Tuberculosis
29%
Drug Susceptibility Testing
28%
Adverse Events
28%
Meta-analysis
27%
Tuberculosis Treatment
26%
Pharmacokinetics
23%
Mycobacterium Infections
23%
Combination Treatment
23%
Monte Carlo Simulation
23%
Medicine Availability
23%
Drug Availability
23%
Medicine Costs
23%
Assessment Method
23%
Pretomanid
23%
Adverse Effects
23%
Pulmonary Tuberculosis
23%
Post-TB
23%
Drug Testing
23%
Clinical Standards
23%
Malnutrition
23%
Adult Patients
23%
Intensive Care Setting
23%
Severity Score
23%
Malnutrition Assessment
23%
Resistance Test
23%
Treatment Efficacy
18%
Intensive Care Unit
17%
WHO European Region
15%
Confidence Interval
14%
TB Treatment
13%
Respiratory Insufficiency
11%
Pharmacokinetics-pharmacodynamics (PK-PD)
11%
QT Prolongation
11%
Safety Profile
11%
Arrhythmia
11%
Treatment Regimen
11%
Tuberculosis Drugs
11%
Treatment Facilities
11%
High-income Countries
11%
Carbapenems
11%
Anti-tuberculosis Drugs
11%
Pharmacology, Toxicology and Pharmaceutical Science
Bedaquiline
98%
Drug Resistant Tuberculosis
96%
Linezolid
68%
Multi-Drug-Resistant Tuberculosis
52%
Rifampicin
49%
Delamanid
47%
Adverse Event
47%
Moxifloxacin
41%
Extensively Drug-Resistant Tuberculosis
39%
Disease
35%
Tuberculosis
31%
Pharmacokinetics
29%
Pretomanid
27%
Hospital Mortality
23%
Lung Tuberculosis
23%
Hospital Infection
23%
Adult Respiratory Distress Syndrome
23%
Therapeutic Drug Monitoring
23%
Acute Respiratory Failure
23%
Coronavirinae
23%
Mortality Rate
23%
Mixed Infection
23%
Hypertensive Factor
23%
Antibiotic Agent
23%
Tuberculostatic Agent
17%
Pharmacodynamics
17%
Levofloxacin
13%
Heart Arrhythmia
11%
QT Prolongation
11%
Atypical Mycobacterium
11%
Respiratory Failure
11%
Carbapenem
11%
Infection
11%
Quinolone Derivative
7%
Carbapenem Derivative
7%
Clofazimine
7%
Drug Safety
7%
Drug Toxicity
5%
Randomized Controlled Trial
5%
Mycobacterium Tuberculosis
5%
Pharmacotherapy
5%
Prevalence
5%
Rifapentine
5%